Melatonin affects the dynamic steady-state equilibrium of estrogen sulfates in human umbilical vein endothelial cells by regulating the balance between estrogen sulfatase and sulfotransferase

González,Alicia; Martínez-Campa,Carlos; Alonso-González,Carolina; Cos,Samuel

doi:10.3892/ijmm.2015.2360

Melatonin affects the dynamic steady-state equilibrium of estrogen sulfates in human umbilical vein endothelial cells by regulating the balance between estrogen sulfatase and sulfotransferase

Authors:
- Alicia González
- Carlos Martínez-Campa
- Carolina Alonso-González
- Samuel Cos
View Affiliations

Affiliations: Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Valdecilla Biomedical Research Institute (IDIVAL), ES-39011 Santander, Spain
Published online on: October 7, 2015 https://doi.org/10.3892/ijmm.2015.2360
Pages: 1671-1676

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melatonin is known to reduce the growth of endocrine-responsive breast cancers by interacting with estrogen signaling pathways. Estrogens play an important role in breast cancer, but also in various types of tissues, including vascular tissue. Estrogen sulfatase (STS) converts inactive estrogen sulfates into active estrogens, whereas estrogen sulfotransferase (EST) sulfonates estrogens to estrogen sulfates. Therefore, STS and EST are considered to be involved in the regulation of local estrogen levels in hormone‑dependent tumors and in non-pathologic tissues, such as those of the vascular system. Estrogens have a major impact on the vasculature, influencing vascular function, the expression of adhesion proteins, angiogenesis and the inflammatory state. In this study, we investigated the status of STS and EST in human umbilical vein endothelial cells (HUVECs) and the modulatory effects of melatonin. Both STS and EST were highly expressed in the HUVECs. The enzymatic activity correlated with the expression levels in these cells. Our findings also demonstrated that melatonin, at physiological concentrations, modulated the synthesis and transformation of biologically active estrogens in HUVECs through the inhibition of STS activity and expression, and the stimulation of EST activity and expression. Since melatonin decreased the STS levels and increased the EST levels, it modified the dynamic steady‑state equilibrium of estrogen sulfates by increasing the inactive estrogen levels and decreasing the active estrogen levels. Therefore, melatonin may modulate the known different biological actions of estrogens in endothelial cells, as well as in estrogen-dependent tumors and non-pathologic tissues.

View Figures

View References

1	Germain D: Estrogen carcinogenesis in breast cancer. Endocrinol Metab Clin North Am. 40:473–484. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pelekanou V and Leclercq G: Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis. Int J Dev Biol. 55:869–878. 2011. View Article : Google Scholar : PubMed/NCBI
3	Russo J and Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 102:89–96. 2006. View Article : Google Scholar : PubMed/NCBI
4	Pasqualini JR and Chetrite GS: Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol. 93:221–236. 2005. View Article : Google Scholar : PubMed/NCBI
5	Stanway SJ, Delavault P, Purohit A, Woo LW, Thurieau C, Potter BV and Reed MJ: Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist. 12:370–374. 2007. View Article : Google Scholar : PubMed/NCBI
6	Pasqualini JR: The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta. 1654:123–143. 2004.PubMed/NCBI
7	Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N and Sasano H: Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer. 12:701–720. 2005. View Article : Google Scholar : PubMed/NCBI
8	Suzuki T, Miki Y, Nakata T, Shiotsu Y, Akinaga S, Inoue K, Ishida T, Kimura M, Moriya T and Sasano H: Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. J Steroid Biochem Mol Biol. 86:449–454. 2003. View Article : Google Scholar : PubMed/NCBI
9	Cos S, González A, Álvarez-García V, Alonso-González C and Martínez-Campa C: Melatonin and breast cancer: selective estrogen enzyme modulator actions. Advances in Cancer Drug Targets. Atta-ur-Rahman: 1. Bentham Science Publishers; Sharjah, UAE: pp. 207–237. 2013
10	Sasano H, Suzuki T, Nakata T and Moriya T: New development in intracrinology of breast carcinoma. Breast Cancer. 13:129–136. 2006. View Article : Google Scholar : PubMed/NCBI
11	Cos S and Sánchez-Barceló EJ: Melatonin and mammary pathological growth. Front Neuroendocrinol. 21:133–170. 2000. View Article : Google Scholar : PubMed/NCBI
12	Cos S and Sánchez-Barceló EJ: Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol. 15:637–647. 2000.PubMed/NCBI
13	Hill SM and Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res. 48:6121–6126. 1988.PubMed/NCBI
14	Blask DE, Sauer LA and Dauchy RT: Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem. 2:113–132. 2002. View Article : Google Scholar : PubMed/NCBI
15	Sánchez-Barceló EJ, Cos S, Fernández R and Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr Relat Cancer. 10:153–159. 2003. View Article : Google Scholar : PubMed/NCBI
16	Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 30:118–128. 2006. View Article : Google Scholar : PubMed/NCBI
17	Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 8:691–702. 2008. View Article : Google Scholar : PubMed/NCBI
18	González A, Cos S, Martínez-Campa C, Alonso-Gonzalez C, Sánchez-Mateos S, Mediavilla MD and Sánchez-Barcelo EJ: Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res. 45:86–92. 2008. View Article : Google Scholar : PubMed/NCBI
19	Álvarez-García V, González A, Martínez-Campa C, Alonso-González C and Cos S: Melatonin modulates aromatase activity and expression in endothelial cells. Oncol Rep. 29:2058–2064. 2013.PubMed/NCBI
20	Cos S, Martínez-Campa C, González A, Álvarez-García V, Alonso-González C, Mediavilla MD and Sánchez-Barceló EJ: Melatonin and aromatase in breast cancer. Clin Cancer Drug. 1:54–64. 2014. View Article : Google Scholar
21	Cos S, Alvarez-García V, González A, Alonso-González C and Martínez-Campa C: Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review). Oncol Lett. 8:487–492. 2014.PubMed/NCBI
22	Alvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Regulation of vascular endo-thelial growth factor by melatonin in human breast cancer cells. J Pineal Res. 54:373–380. 2013.
23	Alvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Antiangiogenic effects of melatonin in endothelial cell cultures. Microvasc Res. 87:25–33. 2013. View Article : Google Scholar : PubMed/NCBI
24	Duncan L, Purohit A, Howarth NM, Potter BV and Reed MJ: Inhibition of estrone sulfatase activity by estrone-3-methylthio-phosphonate: A potential therapeutic agent in breast cancer. Cancer Res. 53:298–303. 1993.PubMed/NCBI
25	Falany CN, Krasnykh V and Falany JL: Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J Steroid Biochem Mol Biol. 52:529–539. 1995. View Article : Google Scholar : PubMed/NCBI
26	Barnabas O, Wang H and Gao XM: Role of estrogen in angiogenesis in cardiovascular diseases. J Geriatr Cardiol. 10:377–382. 2013.
27	Chakrabarti S, Morton JS and Davidge ST: Mechanisms of estrogen effects on the endothelium: An overview. Can J Cardiol. 30:705–712. 2014. View Article : Google Scholar
28	Khalil RA: Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol. 86:1627–1642. 2013. View Article : Google Scholar : PubMed/NCBI
29	Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, et al: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 57:359–383. 2005. View Article : Google Scholar : PubMed/NCBI
30	Bulun SE, Chen D, Lu M, Zhao H, Cheng Y, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, et al: Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol. 106:81–96. 2007. View Article : Google Scholar : PubMed/NCBI
31	Chumsri S and Brodie A: Aromatase inhibitors and breast cancer. Horm Mol Biol Clin Investig. 9:119–126. 2012.PubMed/NCBI
32	Chumsri S: Clinical utilities of aromatase inhibitors in breast cancer. Int J Womens Health. 7:493–499. 2015. View Article : Google Scholar : PubMed/NCBI
33	Shields-Botella J, Bonnet P, Duc I, Duranti E, Meschi S, Cardinali S, Prouheze P, Chaigneau AM, Duranti V, Gribaudo S, et al: In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity. J Steroid Biochem Mol Biol. 84:327–335. 2003. View Article : Google Scholar : PubMed/NCBI
34	Santner SJ, Ohlsson-Wilhelm B and Santen RJ: Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. Int J Cancer. 54:119–124. 1993. View Article : Google Scholar : PubMed/NCBI
35	Hill SM, Spriggs LL, Simon MA, Muraoka H and Blask DE: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett. 64:249–256. 1992. View Article : Google Scholar : PubMed/NCBI
36	Molis TM, Spriggs LL and Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol. 8:1681–1690. 1994.PubMed/NCBI
37	Cos S, Martínez- Campa C, Mediavilla MD and Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. 38:136–142. 2005. View Article : Google Scholar : PubMed/NCBI
38	Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C and Sánchez-Barceló EJ: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer. 118:274–278. 2006. View Article : Google Scholar
39	González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Alvarez-García V, Sánchez-Barceló EJ and Cos S: Inhibitory effects of melatonin on sulfatase and 17β-hydroxysteroid dehydrogenase activity and expression in glioma cells. Oncol Rep. 23:1173–1178. 2010.
40	González A, Alvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. Curr Cancer Drug Targets. 10:279–286. 2010. View Article : Google Scholar : PubMed/NCBI
41	Santner SJ and Santen RJ: Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens. J Steroid Biochem Mol Biol. 45:383–390. 1993. View Article : Google Scholar : PubMed/NCBI
42	Li Y, Xu Y, Li X, Qin Y and Hu R: Effects of PPAR-α agonist and IGF-1 on estrogen sulfotransferase in human vascular endo-thelial and smooth muscle cells. Mol Med Rep. 8:133–139. 2013.PubMed/NCBI
43	Xu Y, Yang X, Wang Z, Li M, Ning Y, Chen S, Yin L and Li X: Estrogen sulfotransferase (SULT1E1) regulates inflammatory response and lipid metabolism of human endothelial cells via PPARγ. Mol Cell Endocrinol. 369:140–149. 2013. View Article : Google Scholar : PubMed/NCBI